Press release
Cardiol Therapeutics (Nasdaq: CRDL) Advances Orphan Drug Designation for CardiolRx Trademark at the American Heart Association...more stocks inside...
CardiolRx Trademark also shows promise in treating myocarditis, a leading cause of sudden cardiac death in younger individuals. With its non-immunosuppressive, anti-inflammatory properties, CardiolRx Trademark offers a safe and convenient oral therapy option, addressing critical gaps in care for patients at high risk of severe cardiac complications.
The compelling MAvERIC-Pilot findings pave the way for the Phase II/III MAVERIC-2 and Phase III MAVERIC-3 clinical trials, targeting broader patient populations. Cardiol is advancing its MAVERIC program while exploring CardiolRx's potential for acute myocarditis and heart failure. With orphan drug designation (ODD) secured, Cardiol Therapeutics is strategically positioned to leverage an accelerated regulatory pathway, potentially transforming treatment for rare and life-threatening heart conditions. See Entire News Article [https://can01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fcfnmedianews.com%2Fcardiol-therapeutics-advancing-orphan-drug-trial-to-phase-2-3%2F&data=05%7C02%7Cchris.firman%40cardiolrx.com%7C1715faf91dfa468709ca08dcff34a8ce%7C6f2a47bd841b4886a2a58b23821e169d%7C0%7C0%7C638665848850043412%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=5My0%2FS5P7%2BjS0e%2FtomRhfTRBgqWgGv2aH4GKgmVObeQ%3D&reserved=0]
Other Stocks to Watch:
* Biodexa Pharmaceuticals (NASDAQ: BDRX): Advancing drug delivery platforms with groundbreaking nanotechnology.
* Cerence Inc. (NASDAQ: CRNC): Revolutionizing automotive AI with cutting-edge voice and virtual assistant technology.
* Safe Pro Inc. (NASDAQ: SPAI): Innovating safety and protective solutions for diverse industries.
* Innovid Corp. (NYSE: CTV): Transforming the advertising landscape with advanced connected TV and video marketing tools.
* Peraso Inc. (NASDAQ: PRSO) received a $3.30 price target and a buy rating following its strong Q3 2024 performance, marked by 20% year-over-year operational efficiency gains and a 34% reduction in operating expenses. Read Entire Report. [https://thestreetreports.com/wp-content/uploads/2024/11/PRSO-Inter-Act-Report.pdf]
These companies, alongside Cardiol Therapeutics (NASDAQ: CRDL), are pushing the boundaries of innovation across various sectors, making them essential to watch for investors and industry enthusiasts alike.
Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content."TSR" is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. "TSR" authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. "TSR" has not been compensated to produce content related to "Any Companies" appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.
Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=cardiol-therapeutics-nasdaq-crdl-advances-orphan-drug-designation-for-cardiolrx-at-the-american-heart-associationmore-stocks-inside]
Country: United States
Website: http://www.thestreetreports.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Cardiol Therapeutics (Nasdaq: CRDL) Advances Orphan Drug Designation for CardiolRx Trademark at the American Heart Association...more stocks inside... here
News-ID: 3750275 • Views: …
More Releases from ABNewswire
Newman's Brew Proves Smooth, Flavorful Coffee Begins with Ethical Sourcing and P …
Newman's Brew has built its reputation on delivering the smoothest coffee available by combining organic bean sourcing with fresh-per-order roasting. The rapidly expanding company demonstrates that ethical business practices and exceptional product quality are not mutually exclusive, while supporting abandoned animal feeding programs as part of its commitment to positive social impact.
In an industry where freshness is often sacrificed for operational convenience, Newman's Brew has chosen a different path. The…
Playground Play Equipment Innovation Sets New Benchmark for Safe, Engaging Space …
As schools, communities, and commercial venues worldwide continue to invest in healthier and more inclusive outdoor environments, playground play equipment [https://www.indooroutdoorplayground.com/what-makes-playground-play-equipment-truly-safe-and-engaging/] is entering a new era-one defined by higher safety standards, smarter design, and broader community engagement. Golden Times (Wenzhou Golden Times Amusement Toys CO., LTD.) today announced an expanded product and market strategy focused on delivering next-generation playground solutions that balance safety, durability, and creativity.
Industry expectations for playgrounds have…
Time.so Reports 300% Growth in Business Users
Time.so reports 300% growth in business users as global teams rely on its fast world clock, city times, time zones, and weather for planning.
Jan 31, 2026 - Time.so today announced a 300% increase in business users, reflecting rising demand for dependable time data across distributed teams, global customer support, and cross border operations.
The surge follows a clear shift in how companies schedule work. Meetings span continents. Deadlines move with daylight…
Shaun Savvy Helps Tuckaway Farm in Bentonville, Arkansas Sell Out Two CSA Season …
Buffalo-based SEO consultant Shaun Savvy partnered with Tuckaway Farm in Bentonville, Arkansas to help the farm sell out two consecutive CSA seasons, generating over $80,000 in revenue while spending less than $1,000 on paid advertising through a strategic blend of local SEO, high-intent content, and targeted social media campaigns.
Shaun Savvy, a Buffalo-based SEO and digital marketing consultant, announced a successful local marketing case study showcasing how Tuckaway Farm sold out…
More Releases for Cardiol
CRDL Stock Price Reflects Investor Confidence in Cardiol Pipeline
Toronto, ON - May 20, 2025 - Cardiol Therapeutics Inc. (NASDAQ: CRDL), a clinical-stage biotech firm developing anti-inflammatory therapies for heart conditions, has provided recent updates highlighting progress in its clinical pipeline and corporate milestones aimed at delivering investor value.
Steady Stock Performance and Financial Strength
CRDL's stock price has demonstrated stability in recent trading, hovering around $1.10 per share. With a cash reserve of approximately $30.6 million, the company has funding…
Pericarditis Drugs Market Is Expected To Reach $816.6 Million By 2031 - Kiniksa …
The latest report on Pericarditis Drugs Market offers valuable insights into emerging trends and pivotal developments within the market. It highlights significant growth opportunities that market participants can leverage, alongside strategic recommendations for capitalizing on these trends. This report serves as an indispensable tool for stakeholders seeking to deepen their understanding of the market landscape and identify actionable pathways for growth. By utilizing this in-depth analysis, stakeholders will gain the…
A Comprehensive Study Exploring Myocarditis Treatment Market | Key Players Cardi …
Market Research Forecast published a new research publication on "Myocarditis Treatment Market Insights, to 2032" with 232 pages and enriched with self-explained Tables and charts in presentable format. In the Study you will find new evolving Trends, Drivers, Restraints, Opportunities generated by targeting market associated stakeholders. The growth of the Myocarditis Treatment market was mainly driven by the increasing R&D spending across the world.
Some of the key players profiled in…
Analysts Consensus Reaffirms Significant Upside Potential for Cardiol Therapeuti …
According to Gantoss, Cardiol Therapeutics (NASDAQ:CRDL) (TSX:CRDL) has many things going in its favor right now heading into a critical Phase 2 trial readout in RP in June that he believes will lead to a positive outcome.
Cardiol Therapeutics (NASDAQ:CRDL) (TSX:CRDL), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, has been attracting substantial interest from investors…
Myocarditis Market to Show Incremental Growth, estimates DelveInsight | Prominen …
DelveInsight's "Myocarditis Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Myocarditis, historical and forecasted epidemiology as well as the Myocarditis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Myocarditis market report provides current treatment practices, emerging drugs, Myocarditis market share of the individual therapies, current and forecasted Myocarditis market Size from 2017 to 2030 segmented by seven…
Cannabis Pharmaceuticals Market 2021 | Rising To The Growth challenges By Cardio …
The use of cannabis in pharmaceuticals is estimated to transform the medical industry due to the properties of cannabis. The use of two components, such as CBD and THC have medicinal properties, which have been proved to treat health conditions such as epilepsy, schizophrenia, arthritis, multiple sclerosis, migraines. At present, across the world, more than 400 active and completed clinical trials are performed for cannabis-based medicinal products.
The cannabis pharmaceuticals market…
